Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy

Salih Subari, Firas Baidoun, Muhanad Hreh, Mrinal M Patnaik, Shahrukh Hashmi, Michelle Elliott, William Hogan, Mark R Litzow, Aref Al-Kali

Research output: Contribution to journalArticle

Abstract

Patients with secondary acute myeloid leukemia (sAML) arising from prior myelodysplastic syndromes have poor prognosis. Anthracycline plus cytarabine (7 + 3) is a standard treatment option for patients who are fit for intensive therapy. In the present study, 22 of 96 sAML patients (23 %) were treated with 7 + 3 and achieved median overall survival (OS) of 9.8 months. Hypomethylating agents (HMA) were given for MDS in 6/22 (28 %) of the patients. When evaluating the prior HMA group, CR/CRi was 50 % for those with prior HMA exposure and 63 % for those without HMA exposure (P = 0.6). Median OS was 14 months for prior HMA exposure vs 10 months for no prior HMA (P = 0.9). The outcome of sAML patients who were treated with 7 + 3 continues to be poor. No statistical significant difference was found between response rates and mOS between prior HMA exposure or not. Additional larger studies are needed to confirm our results.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalInternational Journal of Hematology
Volume103
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • Acute myeloid leukemia
  • Hypomethylating agents
  • Myelodysplasia
  • Secondary

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy'. Together they form a unique fingerprint.

  • Cite this